Jefferies Group LLC restated their hold rating on shares of Mednax, Inc (NYSE:MD) in a report issued on Friday morning. They currently have a $44.00 price objective on the stock.

A number of other analysts also recently weighed in on MD. BidaskClub downgraded shares of Mednax from a hold rating to a sell rating in a report on Friday, July 28th. Mizuho restated a neutral rating and issued a $48.00 target price (down from $62.00) on shares of Mednax in a report on Tuesday, August 1st. Robert W. Baird restated a hold rating and issued a $47.00 target price on shares of Mednax in a report on Sunday, September 3rd. KeyCorp set a $51.00 target price on shares of Mednax and gave the stock a buy rating in a report on Wednesday. Finally, Zacks Investment Research upgraded shares of Mednax from a sell rating to a hold rating in a report on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and two have assigned a buy rating to the stock. The company has an average rating of Hold and a consensus target price of $54.50.

Shares of Mednax (NYSE:MD) traded up $2.02 during mid-day trading on Friday, reaching $43.37. 2,080,514 shares of the company’s stock traded hands, compared to its average volume of 1,302,315. The stock has a market cap of $4,061.82, a PE ratio of 13.26, a P/E/G ratio of 1.41 and a beta of 0.32. Mednax has a 1-year low of $40.56 and a 1-year high of $72.13. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.59 and a current ratio of 1.37.

Mednax (NYSE:MD) last announced its quarterly earnings results on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, hitting the consensus estimate of $0.87. The business had revenue of $868.95 million for the quarter, compared to analysts’ expectations of $864.78 million. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.09 EPS. research analysts forecast that Mednax will post 3.08 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Mednax, Inc (MD) Given “Hold” Rating at Jefferies Group LLC” was published by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/mednax-inc-md-given-hold-rating-at-jefferies-group-llc/1679307.html.

In related news, Director Cesar L. Alvarez sold 10,668 shares of the company’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $42.59, for a total transaction of $454,350.12. Following the transaction, the director now directly owns 44,215 shares in the company, valued at approximately $1,883,116.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total transaction of $128,550.00. Following the transaction, the insider now owns 35,569 shares in the company, valued at $1,524,131.65. The disclosure for this sale can be found here. Corporate insiders own 2.40% of the company’s stock.

Large investors have recently modified their holdings of the stock. Eagle Boston Investment Management Inc. grew its holdings in Mednax by 12.9% during the 2nd quarter. Eagle Boston Investment Management Inc. now owns 191,636 shares of the company’s stock valued at $11,569,000 after purchasing an additional 21,895 shares during the last quarter. Swiss National Bank grew its holdings in Mednax by 3.0% during the 2nd quarter. Swiss National Bank now owns 341,700 shares of the company’s stock valued at $20,628,000 after purchasing an additional 9,900 shares during the last quarter. South Dakota Investment Council grew its holdings in Mednax by 24.5% during the 2nd quarter. South Dakota Investment Council now owns 50,800 shares of the company’s stock valued at $3,067,000 after purchasing an additional 10,000 shares during the last quarter. Nationwide Fund Advisors grew its stake in Mednax by 9.2% in the 2nd quarter. Nationwide Fund Advisors now owns 467,917 shares of the company’s stock worth $28,248,000 after acquiring an additional 39,490 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. grew its stake in Mednax by 527.2% in the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 15,228 shares of the company’s stock worth $919,000 after acquiring an additional 12,800 shares in the last quarter. Institutional investors own 99.97% of the company’s stock.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Analyst Recommendations for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.